Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant interleukin-2, interferon-alpha and 5-fluorouracil after surgery for high-risk renal cell carcinoma
ISRCTN16387614Phase 3Completed
- Sponsor
- Cancer Research UK
- Start
- Feb 1999
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of aldesleukin, interferon alfa and fluorouracil in renal cell carcinoma (RCC) (2 arms), sponsored by Cancer Research UK. Primary endpoints: Disease-free survival and Overall survival. Started Feb 1999; status: completed.
02
Drugs
aldesleukininterferon alfafluorouracil
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ISRCTN16387614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16387614.